Understanding the Unmet Needs in Diagnostics and Therapeutics of Chronic Lymphocytic Leukemia in Korea
{{output}}
Purpose: Since the FDA approval of ibrutinib in 2012, the treatment landscape for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a paradigm shift. Nevertheless, the disease remains incurable... ...
